OTC · Drug Manufacturers - Specialty & Generic

Allergy Therapeutics plc (AGYTF) Stock

$0.15 +0.00% OTC: AGYTF Healthcare

Allergy Therapeutics plc is a biotechnology firm dedicated to the research, development, and commercialization of innovative treatments for allergic conditions. The company offers a variety of allergen-specific immunotherapies, available as both injectable solutions and sublingual (under-the-tongue) formulations.

Valuation

MetricValue
Price$0.15
Market Cap$756.30M
P/E Ratio-5.05
P/B Ratio61.48
P/S Ratio4.40
EPS (TTM)$-0.01
52-Week High$0.15
52-Week Low$0.09
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE409.00%
ROA-68.96%
ROCE-88.54%
Gross Margin41.17%
Operating Margin-60.23%
Net Margin-85.46%
Debt/Equity6.30
Current Ratio1.13

Annual Financials (USD)

Metric20212022202320242025
Revenue$84.0M$73.0M$60.0M$55.0M$76.0M
Operating Profit$4.0M$-12.0M$-40.0M$-35.0M$-28.0M
Net Profit$3.0M$-14.0M$-43.0M$-40.0M$-55.0M
EPS$0.00$-0.01$-0.04$-0.01$-0.01
Op Margin4.8%-16.8%-66.5%-63.9%-37.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$88.0M$74.0M$67.0M$65.0M$68.0M
Total Liabilities$40.0M$35.0M$65.0M$61.0M$131.0M
Cash$40.0M$21.0M$15.0M$13.0M$18.0M
Borrowings$11.0M$11.0M$36.0M$31.0M$60.0M

Latest News

Ilika, Allergy Therapeutics, Ecora Royalties, EGT, Rockfire Resources, Bradda Head Lithium Proactive · Jul 29, 2026 Allergy Therapeutics reports accelerated revenue growth in its second half Proactive · Jul 29, 2026 Cordiant Digital, Helium One, Active Energy, Gaming Realms, Frontier IP, Allergy Therapeutics Proactive · Jul 28, 2026 Allergy Therapeutics names Helge Weiner-Trapness as executive chair Proactive · Jul 28, 2026 Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight PR Newswire · Jul 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$8.0M$-14.0M$-29.0M$-32.0M$-39.0M
Investing Cash Flow$-5.0M$-6.0M$-9.0M$-5.0M$-9.0M
Financing Cash Flow$-2.0M$-2.0M$-4.0M$-5.0M$9.0M
Net Cash Flow$3.0M$-20.0M$-6.0M$-2.0M$1.0M
Free Cash Flow$6.0M$-18.0M$-34.0M$-36.0M$-44.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.36
EV / EBITDA-8.21
FCF Yield-14.81%
Quick Ratio0.70
Interest Coverage-4.41
Return 1Y76.47%
Return 3Y-14.29%
Return 5Y—

Ownership

Insiders Held88.49%
Institutions Held0.01%
Institutions Float Held0.08%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Allergy Therapeutics plc

Allergy Therapeutics plc is a biotechnology firm dedicated to the research, development, and commercialization of innovative treatments for allergic conditions. The company offers a variety of allergen-specific immunotherapies, available as both injectable solutions and sublingual (under-the-tongue) formulations. Their product line includes prescription medications specifically designed to address pollen-related allergies, such as those caused by grasses, weeds, and trees, along with various diagnostic tools. Key products in their portfolio feature names like Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Pollinex, VLP Peanut, and Penicillin diagnostics. Furthermore, Allergy Therapeutics is actively developing new allergy vaccines targeting a range of allergens, including trees, grass, house dust mites, animal dander, and peanuts. The company operates extensively across Central Europe, Southern Europe, the United Kingdom, and extends its market presence internationally. Established in 2004, Allergy Therapeutics plc is based in Worthing, United Kingdom.

Allergy Therapeutics plc is headquartered in GB.

Allergy Therapeutics plc (AGYTF) stock trades at $0.15 with a market capitalization of $756.30M. The stock is valued at a price-to-earnings (P/E) ratio of -5.05, price-to-book of 61.48, price-to-sales of 4.40. Over the past 52 weeks the stock has ranged between $0.09 and $0.15, and currently trades at its 52-week high.

On profitability, Allergy Therapeutics plc generates a return on equity (ROE) of 409.00% — well above the market average, a sign of a high-quality business, return on capital employed of -88.54%, an operating margin of -60.23%, a net profit margin of -85.46%.

Official website: www.allergytherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides